PT - JOURNAL ARTICLE AU - Kurosaki, Akira AU - Hanaoka, Mieko AU - Shintani, Daisuke AU - Miwa, Maiko AU - Yabuno, Akira AU - Yoshida, Hiroyuki AU - Hasegawa, Kosei TI - EP261/#266  Inflammation-related biomarkers for the prediction of prognosis in ovarian cancer patients AID - 10.1136/ijgc-2023-IGCS.333 DP - 2023 Nov 01 TA - International Journal of Gynecologic Cancer PG - A184--A184 VI - 33 IP - Suppl 4 4099 - http://ijgc.bmj.com/content/33/Suppl_4/A184.1.short 4100 - http://ijgc.bmj.com/content/33/Suppl_4/A184.1.full SO - Int J Gynecol Cancer2023 Nov 01; 33 AB - Introduction Most ovarian cancer patients are diagnosed in an advanced stage, and the recurrence rate is also high. But Ovarian cancer is more sensitive to chemotherapy than other carcinomas, therefore many patients receive multiple regimens of chemotherapy. Repeated chemotherapy eventually becomes palliative, however, there are no accurate indicators about whether to continue chemotherapy or not. The clinical usefulness of inflammation-related prognostic biomarkers available from routine blood examination has been reported, e.g., neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), Leukocyte and C-reactive protein score (Prognostic Index, PI) and so on. Moreover, some scoring systems based on circulating blood cell counts and albumin concentration have been also reported to predict cancer patients‘ prognosis, such as the Glasgow prognostic score (GPS), and prognostic nutritional index (PNI). The purpose of this study is to evaluate whether these biomarkers can be indicators for chemotherapy policy decisions.Methods We conducted a retrospective study of patients with ovarian cancer that died after receiving final chemotherapy at our institution from 2007 through 2020. Clinical variables included blood examination data on the day1 of the last chemotherapy.Results We identified 1,405 women treated for ovarian cancer, and 140 patients with ovarian cancer that died after receiving final chemotherapy at our institution. 87.8% were diagnosed with stage III or IV disease. In multivariable analysis, GPS (HR 3.74, p=0.02) and PI (HR 2.75, p=0.04) were independently associated with overall survival.Conclusion/Implications GPS and PI may be useful prognostic predictors for ovarian cancer patients who received multiple chemotherapy regimens.